Mark Lakshmanan

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Mark Lakshmanan, Brian Rayner, Robert S. Busch et al. · The Lancet Diabetes & Endocrinology · 2018 · 635 citations

Medicine, Endocrinology, Pharmacotherapy +11

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures

Per Aspenberg, Harry K. Genant, Torsten Johansson et al. · Journal of Bone and Mineral Research · 2009 · 510 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +17

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Carol Wysham, Thomas Blevins, Richard F. Arakaki et al. · Diabetes Care · 2014 · 387 citations

Pharmacy, Pharmacology, Pharmacotherapy +17